Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shun Lu

Showing results (571-580 of 661) with videos related to

Pageof 67
Sort By:
The Lancet. Respiratory Medicine|September 13, 2024
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
Nature Medicine|April 29, 2025
D3S-001 in advanced solid tumors with KRAS<sup>G12C</sup> mutations: a phase 1 trialByoung Chul Cho, Shun Lu, Myung Ah Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 21, 2022
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of ChinaShun Lu, Qing Zhou, Xiaoqing Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 15, 2020
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)Shun Lu, Jie Wang, Ying Cheng, et al.
The New England Journal of Medicine|April 10, 2024
Alectinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung CancerYi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 22, 2023
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS<sup>G12C</sup> in Patients With NSCLC: Phase 1 Study ResultsZiming Li, Zhengbo Song, Yanqiu Zhao, et al.
Lancet (London, England)|August 9, 2025
Adagrasib versus docetaxel in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trialFabrice Barlesi, Wenxiu Yao, Michaël Duruisseaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2023
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung CancerCharles M Rudin, Stephen V Liu, Ross A Soo, et al.
The Lancet Regional Health. Western Pacific|April 6, 2026
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic <i>MET</i> exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.
Pageof 67

Showing results (571-580 of 661) with videos related to

Sort By:
Pageof 67
The Lancet. Respiratory Medicine|September 13, 2024
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
Nature Medicine|April 29, 2025
D3S-001 in advanced solid tumors with KRAS<sup>G12C</sup> mutations: a phase 1 trialByoung Chul Cho, Shun Lu, Myung Ah Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 21, 2022
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of ChinaShun Lu, Qing Zhou, Xiaoqing Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 15, 2020
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)Shun Lu, Jie Wang, Ying Cheng, et al.
The New England Journal of Medicine|April 10, 2024
Alectinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung CancerYi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 22, 2023
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS<sup>G12C</sup> in Patients With NSCLC: Phase 1 Study ResultsZiming Li, Zhengbo Song, Yanqiu Zhao, et al.
Lancet (London, England)|August 9, 2025
Adagrasib versus docetaxel in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trialFabrice Barlesi, Wenxiu Yao, Michaël Duruisseaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2023
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung CancerCharles M Rudin, Stephen V Liu, Ross A Soo, et al.
The Lancet Regional Health. Western Pacific|April 6, 2026
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic <i>MET</i> exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.
Pageof 67